INT105217

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2002
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 8
Total Number 14
Disease Relevance 6.15
Pain Relevance 3.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Pou4f1) DNA binding (Pou4f1)
Anatomy Link Frequency
trigeminal ganglion 2
embryos 1
neurons 1
developmental stage 1
ganglia 1
Pou4f1 (Mus musculus)
Pain Link Frequency Relevance Heat
nociceptor 231 100.00 Very High Very High Very High
Pain 18 100.00 Very High Very High Very High
trigeminal ganglion 732 99.84 Very High Very High Very High
substance P 24 96.48 Very High Very High Very High
Somatostatin 35 95.96 Very High Very High Very High
Neurotransmitter 18 95.56 Very High Very High Very High
vanilloid receptor subtype 1 3 95.28 Very High Very High Very High
Opioid 1 92.44 High High
gABA 16 90.48 High High
5HT 3 89.60 High High
Disease Link Frequency Relevance Heat
Ganglion Cysts 943 99.84 Very High Very High Very High
Neurodegenerative Disease 41 98.72 Very High Very High Very High
Targeted Disruption 396 98.38 Very High Very High Very High
Repression 61 72.56 Quite High
Nociception 24 35.16 Quite Low
Pain 24 5.00 Very Low Very Low Very Low
Death 14 5.00 Very Low Very Low Very Low
Herpes Simplex Virus 7 5.00 Very Low Very Low Very Low
Adhesions 3 5.00 Very Low Very Low Very Low
Sprains And Strains 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, all transcripts below the x-axis in this plot are probably not direct targets of Brn3a at this developmental stage, and notably this group includes Runx1 and all the Trk-class receptors.
Neg (not) Regulation (targets) of Brn3a in developmental stage
1) Confidence 0.60 Published 2010 Journal Neural Dev Section Body Doc Link PMC2829025 Disease Relevance 0.66 Pain Relevance 0.08
A large number of the downstream targets of Brn3a in the DRG have known roles in neurogenesis or neural function, and include components of axons and synapses, neurotransmitters and their receptors, mediators of intracellular signaling, and transcription factors.
Regulation (targets) of Brn3a in synapses associated with neurotransmitter and neurodegenerative disease
2) Confidence 0.44 Published 2007 Journal Neural Develop Section Body Doc Link PMC1796875 Disease Relevance 0.47 Pain Relevance 0.19
Effect of Brn-3a deficiency on nociceptors and low-threshold mechanoreceptors in the trigeminal ganglion.
Regulation (Effect) of Brn-3a in trigeminal ganglion associated with ganglion cysts, trigeminal ganglion and nociceptor
3) Confidence 0.41 Published 2002 Journal Brain Res. Mol. Brain Res. Section Title Doc Link 12225879 Disease Relevance 0.47 Pain Relevance 0.64
We then plotted the changes in gene expression in the VP16-Brn3a mouse against changes observed in Brn3a knockout TG (Figure 6E), revealing similar regulation of key developmental transcription factors (Figure 6F).
Regulation (changes) of VP16-Brn3a associated with targeted disruption and trigeminal ganglion
4) Confidence 0.39 Published 2010 Journal Neural Dev Section Body Doc Link PMC2829025 Disease Relevance 0.55 Pain Relevance 0.14
However, differences were noted between the Brn3a-/- TG and published results for the Runx1 knockout for the purine receptor P2X3, which is reduced in Runx1-/- DRG but shows little change in the Brn3a-/- TG, and the acid-sensitive channel Accn3, which is increased in Runx1-/- DRG but decreased in the Brn3a knockout.
Neg (little) Regulation (change) of Brn3a associated with targeted disruption and trigeminal ganglion
5) Confidence 0.27 Published 2010 Journal Neural Dev Section Body Doc Link PMC2829025 Disease Relevance 0.62 Pain Relevance 0.67
In transgenic embryos expressing a Brn3a-VP16 dominant transactivator, Runx3 mRNA expression is increased, suggesting that it is a direct regulatory target of Brn3a.
Regulation (target) of Brn3a in embryos associated with targeted disruption
6) Confidence 0.27 Published 2010 Journal Neural Dev Section Abstract Doc Link PMC2829025 Disease Relevance 0.51 Pain Relevance 0.31
Brn3a-VP16 was expressed under control of an 11-kb Brn3a sensory enhancer/promoter, in which the native sequences mediating Brn3a binding have been mutated to eliminate negative autoregulation [21].


Regulation (control) of Brn3a
7) Confidence 0.27 Published 2010 Journal Neural Dev Section Body Doc Link PMC2829025 Disease Relevance 0.09 Pain Relevance 0
Those transcripts with an increased (I) call in greater than half of the nine two-way MAS5 comparisons are highlighted and represent potential direct targets of regulation by Brn3a.
Regulation (regulation) of Brn3a
8) Confidence 0.27 Published 2010 Journal Neural Dev Section Body Doc Link PMC2829025 Disease Relevance 0.50 Pain Relevance 0.17
Comparison of the regulatory targets of Brn3a in the developing DRG with our prior analysis of the TG [20] suggests that there are many downstream genes in common between these ganglia.
Regulation (targets) of Brn3a in ganglia associated with trigeminal ganglion
9) Confidence 0.26 Published 2007 Journal Neural Develop Section Body Doc Link PMC1796875 Disease Relevance 0.42 Pain Relevance 0.17
Effect of Brn-3a deficiency on primary nociceptors in the trigeminal ganglion.
Regulation (Effect) of Brn-3a in trigeminal ganglion associated with ganglion cysts, trigeminal ganglion and nociceptor
10) Confidence 0.26 Published 2005 Journal Neurosci. Res. Section Title Doc Link 15740807 Disease Relevance 0.52 Pain Relevance 1.00
Although the majority of the downstream targets of Brn3a were conserved in the DRG and TG, a subset of genes was uniquely regulated at each axial level.
Regulation (targets) of Brn3a associated with trigeminal ganglion
11) Confidence 0.23 Published 2007 Journal Neural Develop Section Body Doc Link PMC1796875 Disease Relevance 0.79 Pain Relevance 0.45
Conversely, 61.5% of all CFP-labeled cells in the GCL contain Brn-3a immunoreactivity.
Regulation (immunoreactivity) of Brn-3a
12) Confidence 0.17 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2519030 Disease Relevance 0.16 Pain Relevance 0
This is in general agreement with a study that reported Brn-3a immunoreactivity in approximately 35% of all GCL neurons [44].


Regulation (immunoreactivity) of Brn-3a in neurons
13) Confidence 0.17 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2519030 Disease Relevance 0.15 Pain Relevance 0
Brn3a, Islet1, and Klf7 may functionally interact, but are regulated independently, as Brn3a and Islet1 do not regulate one another's expression [54], nor do Brn3a and Klf7 [33].
Neg (independently) Regulation (regulated) of Brn3a
14) Confidence 0.12 Published 2010 Journal Neural Dev Section Body Doc Link PMC2829025 Disease Relevance 0.24 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox